Trial Outcomes & Findings for Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort (NCT NCT03682809)

NCT ID: NCT03682809

Last Updated: 2020-04-06

Results Overview

Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

46 participants

Primary outcome timeframe

Baseline through 2 Weeks

Results posted on

2020-04-06

Participant Flow

Participant milestones

Participant milestones
Measure
Systane Complete
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
Subjects randomized to this group will not receive a treatment.
Overall Study
STARTED
22
24
Overall Study
COMPLETED
22
24
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
Total
n=46 Participants
Total of all reporting groups
Age, Continuous
32.7 Years
n=22 Participants
28.8 Years
n=24 Participants
30.75 Years
n=46 Participants
Sex: Female, Male
Female
20 Participants
n=22 Participants
19 Participants
n=24 Participants
39 Participants
n=46 Participants
Sex: Female, Male
Male
2 Participants
n=22 Participants
5 Participants
n=24 Participants
7 Participants
n=46 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
22 participants
n=22 Participants
24 participants
n=24 Participants
46 participants
n=46 Participants

PRIMARY outcome

Timeframe: Baseline through 2 Weeks

Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.

Outcome measures

Outcome measures
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
Contact Lens Symptoms
Baseline cldeq-8 (worse eye)
20.41 Score on a Scale
Standard Deviation 5.40
18.92 Score on a Scale
Standard Deviation 4.92
Contact Lens Symptoms
2 week cldeq-8 (worse eye)
12.86 Score on a Scale
Standard Deviation 6.40
17.92 Score on a Scale
Standard Deviation 5.30
Contact Lens Symptoms
Baseline cldeq-4 (worse eye)
10.91 Score on a Scale
Standard Deviation 3.28
10.38 Score on a Scale
Standard Deviation 2.41
Contact Lens Symptoms
2 week cldeq-4 (worse eye)
7.14 Score on a Scale
Standard Deviation 3.50
10.13 Score on a Scale
Standard Deviation 2.83

SECONDARY outcome

Timeframe: Baseline through 2 Weeks

Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.

Outcome measures

Outcome measures
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
End of Day Eye Comfort
Speed Score Baseline (worse eye)
10.27 score on a scale
Standard Deviation 3.60
9.67 score on a scale
Standard Deviation 3.93
End of Day Eye Comfort
Speed Score 2 weeks (worse eye)
7.55 score on a scale
Standard Deviation 4.31
9.29 score on a scale
Standard Deviation 4.14

SECONDARY outcome

Timeframe: Baseline through 2 Weeks

Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.

Outcome measures

Outcome measures
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
Corneal Staining
Corneal Staining Extent (baseline)
1.73 Units on a scale
Standard Deviation 2.45
1.63 Units on a scale
Standard Deviation 2.50
Corneal Staining
Corneal Staining Depth (baseline)
1.22 Units on a scale
Standard Deviation 1.54
0.92 Units on a scale
Standard Deviation 1.32
Corneal Staining
Corneal Staining Type (baseline)
1.18 Units on a scale
Standard Deviation 1.56
0.92 Units on a scale
Standard Deviation 1.32
Corneal Staining
Corneal Staining Extent (2 weeks)
1.41 Units on a scale
Standard Deviation 2.42
1.75 Units on a scale
Standard Deviation 1.98
Corneal Staining
Corneal Staining Depth (2 weeks)
0.91 Units on a scale
Standard Deviation 1.38
1.04 Units on a scale
Standard Deviation 1.30
Corneal Staining
Corneal Staining Type (2 weeks)
0.86 Units on a scale
Standard Deviation 1.36
0.92 Units on a scale
Standard Deviation 1.06

SECONDARY outcome

Timeframe: Baseline through 2 Weeks

Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.

Outcome measures

Outcome measures
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
Schirmer's I Test Without Anesthetic
Schirmers Strip Baseline
15.68 mm
Standard Deviation 9.70
20.88 mm
Standard Deviation 10.65
Schirmer's I Test Without Anesthetic
Schirmers Strip (2 weeks)
15.41 mm
Standard Deviation 9.29
18.30 mm
Standard Deviation 10.69

SECONDARY outcome

Timeframe: Baseline through 2 Weeks

Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.

Outcome measures

Outcome measures
Measure
Systane Complete
n=22 Participants
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use. Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
No Treatment
n=24 Participants
Subjects randomized to this group will not receive a treatment.
Tear Break-Up Time (TBUT)
Tear Break Up Time (seconds) (baseline)
7.70 Seconds
Standard Deviation 5.20
8.50 Seconds
Standard Deviation 5.10
Tear Break-Up Time (TBUT)
Tear Break Up Time (seconds) (2 weeks)
8.57 Seconds
Standard Deviation 4.73
8.80 Seconds
Standard Deviation 5.08

Adverse Events

Systane Complete

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Andrew Pucker

The University of Alabama at Birmingham

Phone: 920-579-2900

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place